Launch of brain health study with Oura

Cambridge Cognition Holdings PLC

28 May 2026

 

Cambridge Cognition Holdings plc

("Cambridge Cognition", the "Company" or the "Group")

Cambridge Cognition and Oura launch large-scale brain health study integrating cognition with wearable sleep and physiological data

Cambridge, UK, 28 May 2026: Cambridge Cognition Holdings plc (AIM: COG), the neuroscience technology company whose digital cognitive assessments drive scientific discovery, accelerate drug development and improve patient care, announces a collaboration with ŌURA, maker of the world's leading smart ring, on a new institutional review board (IRB)-approved brain health study. Conducted through Oura Labs, an experimental innovation platform within the Oura App, the study pairs Cambridge Cognition's scientifically validated digital cognitive assessments with Oura's continuous physiological data. Rather than focusing only on diagnosed disease, this work explores how everyday patterns in rest, stress, and behaviour may relate to cognitive function and performance over time.

Oura has established one of the world's leading consumer health platforms, with sensing technology spanning sleep, activity, stress, cardiovascular and metabolic health and more, alongside partnerships with more than 1,200 leading organisations across health, wellness, and commercial brands.

Cambridge Cognition's scientifically validated digital cognitive assessments from CANTAB Pathway™ have been integrated into the Oura platform as short in-app tasks, specifically CANTAB One and CANTAB Insight. As part of this large-scale remote observational research programme running through 2026, up to 45,000 participating Oura members will complete these brief assessments alongside continuous monitoring of their sleep, activity, stress and physiological measurements captured by Oura Ring.

The study is intended to explore relationships between behavioural, biometric and cognitive measures over time, helping advance understanding of how factors such as sleep, recovery and activity may influence brain health and cognition. The programme is also designed to assess user engagement with consumer-integrated cognitive assessments alongside wearable-derived and self-reported health data. Insights generated from these combined datasets are expected to help inform future product development and scalable brain health applications.

The collaboration builds on the recent expansion of CANTAB Pathway™ across healthcare and consumer markets and reflects Cambridge Cognition's strategy of making its cognitive assessments more accessible through scalable digital platforms. Building on previous programmes including Project Intuition, a 23,000-participant remote cognitive assessment study conducted with Biogen and Apple, this demonstrates the Company's ability to deploy validated cognitive measurement at scale and generate rich longitudinal insight into cognitive function.

Rob Baker, CEO, Cambridge Cognition said, "Oura combines strong scientific credibility with significant consumer reach, making them an ideal partner on this study as we seek to expand CANTAB Pathway™ into broader healthcare and consumer applications. Bringing together trusted cognitive science with wearable-derived physiological data is a powerful way to support scalable approaches to brain health measurement, and to extend the reach of our technology beyond traditional clinical and research environments."

"Cognitive health is one of the least understood frontiers in preventive medicine," said Shyamal Patel, Ph.D., Senior Vice President of Science at Oura. "By pairing validated cognitive assessments with continuous sleep, activity, and physiological sensing, this Brain Health Study allows us to rigorously explore how everyday biometrics and behaviors relate to cognitive performance over time, laying a scientific foundation for future tools that can help people understand and support their long-term brain health."

INVESTOR PRESENTATIONS

A pre-recorded presentation on the announcement is available to view through Investor Meet Company: https://www.investormeetcompany.com/companies/cambridge-cognition-holdings-plc/updates.

ENQUIRIES

Cambridge Cognition Holdings plc Rob Baker, Chief Executive Officer Ronald Openshaw, Chief Financial Officer	Tel: [phone] [e-mail]
Cavendish Capital Markets Limited (NOMAD and Joint Broker) Geoff Nash / Elysia Bough / Joe Smith Harriet Ward Nigel Birks	Tel: [phone] Corporate Finance Corporate Broking LS Specialist Sales
Singer Capital Markets Limited (Joint Broker) Amber Higgs / James Serjeant / Daniel Ingram	Tel: [phone]

The information contained within this announcement is deemed to constitute inside information as stipulated under the retained EU law version of the Market Abuse Regulation (EU) No. 596/2014 (the "UK MAR") which is part of UK law by virtue of the European Union (Withdrawal) Act 2018. The information is disclosed in accordance with the Company's obligations under Article 17 of the UK MAR. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

NOTES TO EDITORS

ABOUT CAMBRIDGE COGNITION AND CANTAB PATHWAY™

Cambridge Cognition is a neuroscience technology company whose digital cognitive assessments support scientific discovery, accelerate drug development and improve patient care. 

The Company has developed a suite of touchscreen and voice-based cognitive assessments delivered under the CANTAB and Winterlight brands.  These assessments are designed to:

·    require minimal specialist administration

·    deliver objective results in real time or shortly after completion

·    reduce administrator bias

·    support longitudinal monitoring of cognitive function

Assessment results can be presented in formats appropriate for both consumers in home-use settings and healthcare professionals in clinical or research environments. 

CANTAB Pathway™ is Cambridge Cognition's latest scalable cognitive assessment solution, structured as an escalating series of tasks for use in consumer and healthcare settings:

·    CANTAB One - a brief assessment of overall cognitive function

·    CANTAB Insight™ - a three-task battery providing deeper insight across five cognitive sub-domains

·    CANTAB Plus - specialist disease-specific modules for use by appropriately qualified healthcare professionals, covering eight indications including Parkinson's disease, ADHD, multiple sclerosis, Huntington's disease, schizophrenia, depression, and Alzheimer's disease and related dementias

For further information, visit: www.cambridgecognition.com 

About ŌURA

ŌURA delivers personalized health data, insights, and daily guidance with Oura Ring, the leading smart ring that helps you live healthier, longer. Guided by a mission to shift healthcare from sick care to prevention, ŌURA supports millions of members worldwide across sleep, activity, stress, readiness, women's health, and heart health. Scientifically validated against medical gold standards, the lightweight Oura Ring tracks 50+ health metrics continuously, empowering both individuals and thousands of research teams, healthcare providers, and organizations. With 1,000 ecosystem partners across wellness and medicine, ŌURA is advancing the future of preventative health. Learn more at ouraring.com or connect with ŌURA on Instagram, LinkedIn, and TikTok.

Oura Ring is not a medical device and is not intended to diagnose, treat, cure, monitor, or prevent medical conditions or illnesses.

 

END